Ultimo aggiornamento: agosto 17, 2026

Mortality due to end-stage liver disease ranks as the 12th leading cause of death in the United States. Liver transplantation remains the primary treatment for this condition, but a severe shortage of organ donors highlights the urgent need for alternative therapeutic approaches.

Stem Cell Therapy Using mRNA Technology
Lo studio, published in Cell Stem Cell
, unveils a novel stem cell treatment employing mRNA technology encapsulated into lipid nanoparticles (LNP). This technology, previously successful in the development of COVID-19 vaccines, demonstrates the potential to enhance the natural repair mechanism of the liver. The research identifies a specific receptor on stem cells that can be activated by the ligand protein, vascular endothelial growth factor A (VEGFA). This discovery opens avenues for potential non-invasive treatment options for chronic liver disease.

To comprehend the therapeutic potential, researchers conducted studies on zebrafish and mice liver disease models. In zebrafish subjected to induced liver disease, exposure to VEGFA resulted in a significant increase in newly generated epatociti. Mouse studies, inducing acute and chronic liver diseases, demonstrated that VEGFA mRNA-LNP injections induced robust conversion of biliary epithelial cells (BEC) to hepatocytes, showcasing a five-fold increase compared to control-treated mice. Inoltre, the treatment exhibited full reversion of steatosis and fibrosis in the chronic model.

Implications for Clinical Care and Future Perspectives
The potential of this stem cell therapy is far-reaching, offering a mechanism for the liver to heal itself, potentially reducing the need for liver transplants. The treatment activates liver stem cells, fostering the proliferation of biliary epithelial cells and generating new, healthy hepatocytes. In particolare, the study suggests that VEGFA mRNA-LNP could serve as an alternative treatment for severe acetaminophen intoxication, preventing liver failure and reducing the need for transplantation in cases where conventional interventions prove time-limited. This breakthrough opens avenues for novel treatments, utilizing the liver’s natural repair mechanism, bringing hope to those suffering from chronic liver diseases and challenging the current transplantation paradigm

Revisione scientifica di casi

Revisione scientifica del caso

Ti piacerebbe capire se i programmi clinici sono attuali, recenti sviluppi della ricerca, o potrebbero esserlo gli approcci emergenti rilevante per la tua situazione individuale?

Condividi la tua domanda con il nostro team di ricerca scientifica e ricevi informazioni focalizzate sulle aree di ricerca attuale che potrebbero essere pertinente al tuo caso.

  • Revisione delle informazioni fornite
  • Informazioni rilevanti sulla ricerca e sul programma clinico
  • Una risposta chiara focalizzata sulla tua situazione
Cosa succede dopo? Invia la tua domanda, ricevere una revisione scientifica mirata, e ottieni una risposta chiara sulla ricerca e sui programmi clinici rilevanti per la tua situazione.
La tua revisione scientifica sarà preparata da Dott. Helen Melnik, Dottorato di ricerca , chi ha più di 25 anni di esperienza nella ricerca sulle cellule staminali e nei programmi clinici internazionali.

Nessun obbligo. La tua domanda verrà esaminata in modo confidenziale.

Solo informazioni didattiche e di ricerca. Questo servizio no costituiscono un parere medico, diagnosi, prescrizione, o uno personalizzato raccomandazione terapeutica.


NBScienza

organizzazione di ricerca a contratto

Whatsapp